Arcturus Therapeutics - ARCT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.43
  • Forecasted Upside: 55.84%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$36.21
▼ -0.71 (-1.92%)

This chart shows the closing price for ARCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcturus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARCT

Analyst Price Target is $56.43
▲ +55.84% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $56.43, with a high forecast of $90.00 and a low forecast of $36.00. The average price target represents a 55.84% upside from the last price of $36.21.

This chart shows the closing price for ARCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Arcturus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2024CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $48.00Low
12/13/2023Canaccord Genuity GroupInitiated CoverageBuyLow
12/13/2023Canaccord Genuity GroupInitiated CoverageBuy$90.00Low
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
11/15/2023William BlairReiterated RatingOutperformLow
11/6/2023William BlairReiterated RatingOutperformLow
9/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
9/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
7/24/2023William BlairInitiated CoverageOutperform$71.00Low
7/17/2023Wells Fargo & CompanyBoost Target$35.00 ➝ $45.00Low
7/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
7/14/2023GuggenheimReiterated RatingBuyLow
7/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00Low
5/15/2023Cantor FitzgeraldReiterated RatingOverweightLow
5/11/2023HC WainwrightUpgradeNeutral ➝ Buy$19.00 ➝ $51.00Low
3/29/2023HC WainwrightReiterated RatingNeutral$19.00Low
3/29/2023GuggenheimReiterated RatingBuy$36.00Low
11/14/2022Wells Fargo & CompanyInitiated CoverageOverweight$35.00Low
11/10/2022The Goldman Sachs GroupBoost TargetSell$8.00 ➝ $14.00Low
11/10/2022Robert W. BairdDowngradeNeutral ➝ Underperform$18.00Low
11/3/2022CitigroupUpgradeNeutral ➝ Buy$22.00 ➝ $35.00Low
11/2/2022BarclaysUpgradeUnderweight ➝ Equal Weight$16.00 ➝ $25.00Low
11/2/2022Cantor FitzgeraldBoost TargetOverweight$39.00 ➝ $44.00Low
8/10/2022Brookline Capital ManagementReiterated RatingBuyLow
8/10/2022Wells Fargo & CompanyLower TargetOverweight$105.00 ➝ $98.00Low
8/10/2022BarclaysLower TargetUnderweight$17.00 ➝ $16.00Low
8/10/2022Raymond JamesDowngradeMarket Perform ➝ UnderperformLow
5/24/2022The Goldman Sachs GroupLower TargetSell$14.00 ➝ $8.00High
5/11/2022GuggenheimLower Target$83.00 ➝ $36.00High
5/11/2022Robert W. BairdUpgradeUnderperform ➝ Neutral$21.00 ➝ $18.00High
5/10/2022BarclaysLower Target$21.00 ➝ $17.00High
5/10/2022HC WainwrightLower Target$25.00 ➝ $19.00High
5/9/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/21/2022CitigroupDowngradeBuy ➝ Neutral$86.00 ➝ $29.00High
3/25/2022Wells Fargo & CompanyLower TargetOverweight$107.00 ➝ $105.00Medium
3/15/2022CitigroupLower TargetBuy$114.00 ➝ $86.00Low
3/1/2022HC WainwrightLower Target$47.00 ➝ $25.00High
3/1/2022Wells Fargo & CompanyLower TargetOverweight$118.00 ➝ $107.00Low
3/1/2022Cantor FitzgeraldLower Target$93.00 ➝ $86.00Low
3/1/2022BarclaysLower Target$31.00 ➝ $21.00Low
1/31/2022Raymond JamesUpgradeUnderperform ➝ Market PerformHigh
1/26/2022HC WainwrightLower Target$47.00 ➝ $33.00High
11/16/2021Cantor FitzgeraldBoost TargetOverweight$85.00 ➝ $93.00Low
11/9/2021BarclaysLower TargetPositive ➝ Underweight$46.00 ➝ $31.00High
8/25/2021CitigroupLower TargetBuy$118.00 ➝ $114.00High
8/12/2021Raymond JamesDowngradeMarket Perform ➝ UnderperformHigh
8/10/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$29.00High
8/10/2021Cantor FitzgeraldBoost TargetOverweight$71.00 ➝ $85.00High
8/10/2021Robert W. BairdDowngradeNeutral ➝ Underperform$31.00High
7/2/2021Cantor FitzgeraldInitiated CoverageOverweight$71.00High
6/24/2021The Goldman Sachs GroupInitiated CoverageNeutral$29.00 ➝ $34.00Low
6/21/2021BarclaysDowngradeEqual Weight ➝ Underweight$33.00 ➝ $25.00High
5/12/2021B. RileyReiterated RatingSell$35.00 ➝ $23.00Low
5/11/2021BarclaysLower TargetEqual Weight$46.00 ➝ $33.00High
3/8/2021B. RileyLower TargetPositive ➝ Sell$45.00 ➝ $35.00Low
3/2/2021Roth CapitalLower TargetSell$77.00 ➝ $45.00Low
2/17/2021B. RileyDowngradeNeutral ➝ SellLow
1/15/2021B. RileyDowngradeBuy ➝ Neutral$138.00 ➝ $77.00Medium
1/7/2021Wells Fargo & CompanyInitiated CoverageOverweight$118.00N/A
12/29/2020HC WainwrightDowngradeBuy ➝ Neutral$84.00 ➝ $50.00N/A
12/29/2020Robert W. BairdDowngradeOutperform ➝ Neutral$79.00 ➝ $69.00N/A
12/29/2020BarclaysDowngradeOverweight ➝ Equal Weight$68.00 ➝ $46.00N/A
12/29/2020Raymond JamesDowngradeOutperform ➝ Market Perform$46.00N/A
12/23/2020Roth CapitalDowngradeBuy ➝ Sell$77.00N/A
12/14/2020Smith Barney CitigroupBoost Target$62.00 ➝ $133.00Medium
12/7/2020B. RileyBoost TargetBuy$64.00 ➝ $111.00High
11/11/2020B. RileyLower TargetBuy$82.00 ➝ $64.00High
11/10/2020Raymond JamesLower TargetOutperform$79.00 ➝ $73.00High
10/26/2020BarclaysInitiated CoverageOverweight$72.00Medium
10/6/2020CitigroupInitiated CoverageBuy ➝ Buy$65.00High
8/25/2020Piper SandlerInitiated CoverageOverweight$77.00Medium
8/12/2020B. RileyBoost Target$70.00 ➝ $82.00Medium
8/11/2020Brookline Capital ManagementReiterated RatingBuyLow
8/11/2020Raymond JamesBoost TargetOutperform$72.00 ➝ $79.00High
8/11/2020HC WainwrightReiterated RatingBuy$78.00High
7/30/2020Roth CapitalInitiated CoverageBuy$77.00Medium
7/24/2020Raymond JamesReiterated RatingBuyHigh
7/24/2020HC WainwrightBoost TargetBuy$62.00 ➝ $78.00High
7/16/2020Raymond JamesInitiated CoverageOutperform$72.00Medium
7/12/2020B. RileyInitiated CoverageBuy$70.00High
6/9/2020WBB SecuritiesDowngradeBuy ➝ Hold$31.00Low
5/4/2020HC WainwrightReiterated RatingBuy$62.00Low
4/28/2020HC WainwrightBoost TargetBuy$26.00 ➝ $62.00High
4/14/2020HC WainwrightBoost TargetBuy$24.00 ➝ $26.00High
3/18/2020Robert W. BairdReiterated RatingBuy$26.00High
3/12/2020HC WainwrightBoost TargetBuy$18.00 ➝ $24.00High
3/5/2020LADENBURG THALM/SH SHBoost Target$22.00 ➝ $28.00High
3/4/2020HC WainwrightReiterated RatingBuy$18.00High
3/4/2020Roth CapitalBoost TargetBuy$14.00 ➝ $24.00High
2/10/2020Robert W. BairdInitiated CoverageOutperform$24.00High
2/6/2020GuggenheimInitiated CoverageBuy$19.00High
1/9/2020HC WainwrightReiterated RatingBuy$18.00Low
8/16/2019HC WainwrightSet TargetBuy$18.00High
8/7/2019HC WainwrightBoost TargetBuy$16.00 ➝ $18.00Medium
7/24/2019Brookline Capital ManagementReiterated RatingBuyHigh
6/20/2019Chardan CapitalSet TargetBuy$18.00High
4/5/2019HC WainwrightInitiated CoverageBuy ➝ Buy$15.00Low
3/19/2019Chardan CapitalReiterated RatingBuy$18.00Medium
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2023
  • 7 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/24/2023
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024

Current Sentiment

  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Arcturus Therapeutics logo
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $36.21
Low: $35.69
High: $36.98

50 Day Range

MA: $33.50
Low: $25.95
High: $41.62

52 Week Range

Now: $36.21
Low: $14.21
High: $41.68

Volume

396,715 shs

Average Volume

366,048 shs

Market Capitalization

$967.53 million

P/E Ratio

10.03

Dividend Yield

N/A

Beta

2.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcturus Therapeutics?

The following Wall Street research analysts have issued research reports on Arcturus Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, StockNews.com, TheStreet, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ARCT.

What is the current price target for Arcturus Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Arcturus Therapeutics in the last year. Their average twelve-month price target is $56.43, suggesting a possible upside of 55.8%. Canaccord Genuity Group Inc. has the highest price target set, predicting ARCT will reach $90.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $36.00 for Arcturus Therapeutics in the next year.
View the latest price targets for ARCT.

What is the current consensus analyst rating for Arcturus Therapeutics?

Arcturus Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARCT will outperform the market and that investors should add to their positions of Arcturus Therapeutics.
View the latest ratings for ARCT.

What other companies compete with Arcturus Therapeutics?

How do I contact Arcturus Therapeutics' investor relations team?

Arcturus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 900-2660 and its investor relations email address is [email protected]. The official website for Arcturus Therapeutics is www.arcturusrx.com. Learn More about contacing Arcturus Therapeutics investor relations.